Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Argenta Announces Fourth Extension of Drug Discovery Collaboration with Genentech

Published: Monday, October 14, 2013
Last Updated: Monday, October 14, 2013
Bookmark and Share
Agreement covers a portfolio of projects that utilizes Argenta's drug discovery expertise.

Argenta has announced a three-year extension of its integrated contract drug discovery agreement with Genentech, a member of the Roche Group.

This is the fourth such extension since the agreement was first announced in December 2005. The agreement covers a portfolio of projects that utilizes Argenta's wide-ranging drug discovery expertise to discover new chemical entities acting against undisclosed drug targets defined by Genentech.

Dr John Montana, Managing Director of Argenta, commented, “We are delighted that our long-standing and highly valued client, Genentech, has once again chosen to extend its collaboration with Argenta. We believe that this further extension is a testament both to the close working relationship that has been established between our companies over the years and the high level of success delivered by Argenta to Genentech in terms of pre-clinical candidate compounds, four of which are currently in clinical trials”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Argenta, Antabio Achieve Milestone in Anti-bacterial Drug Discovery Collaboration
Argenta has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug discovery project funded by the Wellcome Trust.
Monday, March 10, 2014
Argenta Announces Record Year for Peer-Reviewed Publications
Publications have been co-authored with clients such as Genentech, AstraZeneca and Corcept.
Tuesday, December 10, 2013
Argenta and Pcovery Announce Drug Discovery Collaboration
Under the terms of the agreement, Argenta will provide medicinal chemistry and computer-aided drug design services to assist Pcovery.
Tuesday, July 16, 2013
Argenta and ANTABIO Announce Drug Discovery Collaboration
Programme will focus on novel antibacterial agents.
Friday, February 08, 2013
Argenta Delivers Preclinical Candidate for Wellcome Trust Funded Anti-Aging Project
The three-year project aimed at identifying selective inhibitors of the 11beta-HSD1 enzyme resulted in the identification of a lead candidate.
Tuesday, October 19, 2010
Argenta Expands Collaboration with Genentech to Include BioFocus
Under the amendment, BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.
Thursday, September 16, 2010
Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
This is the second extension of the contract drug discovery agreement since the first collaboration was announced in December 2005.
Friday, May 22, 2009
Argenta Discovery and Porsolt Join Forces to Provide CNS and Pain Contract Drug Discovery Services
The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for clients.
Wednesday, May 20, 2009
Argenta Discovery and PRECOS Establish Cancer Drug Discovery Alliance
The alliance will provide exceptional cancer drug discovery services and expertise on a fee-for-service basis.
Thursday, February 19, 2009
Argenta Discovery Announces the Initiation of a Phase II Clinical Trial with ADC4022
The Phase II study is a multi-centre, randomized, double-blind, placebo-controlled study to evaluate the effect of inhaled ADC4022.
Monday, March 10, 2008
Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
The two programmes under the agreement utilize Argenta's expertise to discover new chemical entities acting against undisclosed drug targets defined by Genentech.
Wednesday, October 24, 2007
Argenta Discovery Announces Contract Drug Discovery Collaboration with BioTie Therapies
Scientists from the two companies will exploit Argenta’s expertise in medicinal chemistry, computer-aided drug design and early ADME to advance one of BioTie’s therapeutics programmes.
Friday, April 06, 2007
Argenta Announces Collaboration with PainCeptor
Scientists from the two companies will exploit Argenta’s expertise in computer-aided drug design and medicinal chemistry.
Monday, May 01, 2006
Argenta Discovery collaboration with Corcept Therapeutics

Wednesday, May 07, 2003
Scientific News
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
`Molecular Commando’ Identified to Tackle Hypoxia Pathway
Scientists identify 'molecular commando' that can activate hypoxic response, which helps combat a number of conditions.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Two Antibiotics Fight Bacteria Differently Than Thought
Researchers discover that two widely prescribed antibiotics may fight bacteria differently than previously thought.
Drug Target for Gastrointestinal Stromal Tumors Identified
Researchers show the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!